Myrobalan Therapeutics Overview
- Year Founded
-
2021
- Status
-
Private
- Employees
-
15
- Latest Deal Type
-
Grant
- Latest Deal Amount
-
$850K
- Investors
-
9
Myrobalan Therapeutics General Information
Description
Operator of a therapeutic biotechnology company intended for developing oral neurorestorative therapies. The company offers neurological processes such as demyelination and neuroinflammation and innovative drug discovery tools to create selective and brain-penetrant therapeutic candidates that are positioned for addressing unmet medical needs in CNS diseases, enabling healthcare professionals to provide therapeutic opportunities for a large patient population with unmet medical needs.
Contact Information
Website
www.myrotx.comCorporate Office
- 200 Boston Avenue
- Suite G750
- Medford, MA 02155
- United States
Corporate Office
- 200 Boston Avenue
- Suite G750
- Medford, MA 02155
- United States
Myrobalan Therapeutics Timeline
Myrobalan Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Grant | 13-Mar-2025 | $850K | Completed | Generating Revenue | ||
| 5. Grant | 07-Feb-2024 | Completed | Generating Revenue | |||
| 4. Early Stage VC (Series A) | 10-Jan-2024 | Completed | Generating Revenue | |||
| 3. Accelerator/Incubator | 01-Apr-2023 | Completed | Generating Revenue | |||
| 2. Accelerator/Incubator | 01-Dec-2022 | $10M | Completed | Generating Revenue | ||
| 1. Seed Round | 01-Apr-2022 | $10M | $10M | Completed | Pre-Clinical Trials |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Myrobalan Therapeutics Patents
Myrobalan Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026213397-A1 | Salt and polymorph forms of csf-1r inhibitor | Pending | 03-Apr-2025 | ||
| WO-2025195241-A1 | Gpr17 receptor inhibitor and use thereof | Pending | 19-Mar-2024 | ||
| WO-2024217523-A1 | Selective tky2 inhibitors and uses thereof | Inactive | 20-Apr-2023 | ||
| WO-2024211708-A1 | Tyk2 inhibitors for treatment of glaucoma | Inactive | 06-Apr-2023 | ||
| AU-2023380534-A1 | Gpr17 modulators and uses thereof | Pending | 20-Nov-2022 | C07D471/04 |
Myrobalan Therapeutics Signals
Myrobalan Therapeutics Investors (9)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| National Multiple Sclerosis Society (NMSS) | Not-For-Profit Venture Capital | |||
| The ALS Association | Not-For-Profit Venture Capital | |||
| AB Magnitude Ventures Group | Venture Capital | Minority | ||
| Co-Win Ventures | Venture Capital | Minority | ||
| Guanzi Private Equity Fund Management | Growth/Expansion | Minority |
Myrobalan Therapeutics FAQs
-
When was Myrobalan Therapeutics founded?
Myrobalan Therapeutics was founded in 2021.
-
Where is Myrobalan Therapeutics headquartered?
Myrobalan Therapeutics is headquartered in Medford, MA.
-
What is the size of Myrobalan Therapeutics?
Myrobalan Therapeutics has 15 total employees.
-
What industry is Myrobalan Therapeutics in?
Myrobalan Therapeutics’s primary industry is Drug Discovery.
-
Is Myrobalan Therapeutics a private or public company?
Myrobalan Therapeutics is a Private company.
-
What is Myrobalan Therapeutics’s current revenue?
The current revenue for Myrobalan Therapeutics is .
-
How much funding has Myrobalan Therapeutics raised over time?
Myrobalan Therapeutics has raised $43M.
-
Who are Myrobalan Therapeutics’s investors?
National Multiple Sclerosis Society (NMSS), The ALS Association, AB Magnitude Ventures Group, Co-Win Ventures, and Guanzi Private Equity Fund Management are 5 of 9 investors who have invested in Myrobalan Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process